Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma

Published:2017-08 Issue:2 Volume:284 Page:583-592
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Zhong Bin-Yan¹,Ni Cai-Fang¹,Chen Li¹,Zhu Hai-Dong¹,Teng Gao-Jun¹

Affiliation:

1. From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of Soochow University, Suzhou, China (C.F.N.).

Funder

National Natural Science Foundation of China

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2017161975

Reference36 articles.

1. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

3. Sorafenib in Advanced Hepatocellular Carcinoma